Driessen RJ - Search Results

1

Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.

Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM. Driessen RJ, et al. Br J Dermatol. 2009 Mar;160(3):670-5. doi: 10.1111/j.1365-2133.2008.09019.x. Epub 2008 Jan 28. Br J Dermatol. 2009. PMID: 19210502

2

Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice.

Berends MA, Driessen RJ, Langewouters AM, Boezeman JB, Van De Kerkhof PC, De Jong EM. Berends MA, et al. Among authors: driessen rj. J Dermatolog Treat. 2007;18(2):76-83. doi: 10.1080/09546630601121086. J Dermatolog Treat. 2007. PMID: 17520463 Free article. Clinical Trial.

3

Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome.

Driessen RJ, Berends MA, Boezeman JB, van de Kerkhof PC, de Jong EM. Driessen RJ, et al. Br J Dermatol. 2008 May;158(5):1098-106. doi: 10.1111/j.1365-2133.2008.08514.x. Epub 2008 Mar 29. Br J Dermatol. 2008. PMID: 18384440

4

Etanercept combined with methotrexate for high-need psoriasis.

Driessen RJ, van de Kerkhof PC, de Jong EM. Driessen RJ, et al. Br J Dermatol. 2008 Aug;159(2):460-3. doi: 10.1111/j.1365-2133.2008.08669.x. Epub 2008 Jun 28. Br J Dermatol. 2008. PMID: 18547310

5

Analysis of 3-year national reimbursement application data on etanercept and efalizumab for psoriasis.

Driessen RJ, de Jong EM, de Rie MA, Salemink GW, van de Kerkhof PC. Driessen RJ, et al. Br J Dermatol. 2008 Sep;159(3):760-1. doi: 10.1111/j.1365-2133.2008.08729.x. Epub 2008 Jul 8. Br J Dermatol. 2008. PMID: 18627373 No abstract available.

6

Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies.

Driessen RJ, Boezeman JB, Van De Kerkhof PC, De Jong EM. Driessen RJ, et al. J Dermatolog Treat. 2009;20(1):42-7. doi: 10.1080/09546630802225702. J Dermatolog Treat. 2009. PMID: 18649164 Free article.

7

Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement.

van Lingen RG, van Erp PE, Seyger MM, de Jong EM, de Boer-van Huizen RT, Driessen RJ, van de Kerkhof PC. van Lingen RG, et al. Among authors: driessen rj. Acta Derm Venereol. 2009;89(5):518-20. doi: 10.2340/00015555-0675. Acta Derm Venereol. 2009. PMID: 19734982 Free article. Clinical Trial. No abstract available.

8

Daily practice assessment of liver injury in patients with psoriasis on methotrexate.

Driessen RJ, van de Kerkhof PC, de Jong EM. Driessen RJ, et al. Br J Dermatol. 2010 Jan;162(1):211-3. doi: 10.1111/j.1365-2133.2009.09498.x. Epub 2009 Nov 6. Br J Dermatol. 2010. PMID: 19903179 No abstract available.

9

Analysis of 4-year Dutch reimbursement application data of biological therapies for psoriatic arthritis.

Driessen RJ, de Jong EM, Salemink GW, Bürer JH, van de Kerkhof PC, van den Hoogen FH. Driessen RJ, et al. Rheumatology (Oxford). 2010 Mar;49(3):588-91. doi: 10.1093/rheumatology/kep428. Epub 2009 Dec 29. Rheumatology (Oxford). 2010. PMID: 20040525

10

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.

Lecluse LL, Driessen RJ, Spuls PI, de Jong EM, Stapel SO, van Doorn MB, Bos JD, Wolbink GJ. Lecluse LL, et al. Among authors: driessen rj. Arch Dermatol. 2010 Feb;146(2):127-32. doi: 10.1001/archdermatol.2009.347. Arch Dermatol. 2010. PMID: 20157022

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters